A large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in people with dementia, a condition for which no treatments are currently licensed.
New data presented at the Alzheimer’s Association International Conference indicates that pimavanserin leads to a robust reduction in the severity of psychosis symptoms during the 12 week open-label phase of the study, regardless of the underlying dementia subtype or the severity of participants’ dementia.
The international phase three relapse-prevention trial was conducted in collaboration with the University of Exeter, working with Acadia Pharmaceuticals. The trial enrolled 392 participants who…
